Navigation Links
Orexigen(R) Therapeutics to Speak at Ninth Annual JMP Securities Research Conference
Date:5/10/2010

SAN DIEGO, May 10 /PRNewswire-FirstCall/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, today announced that the Company will be speaking at the Ninth Annual JMP Securities Research Conference.  The details are as follows:  

Date:  May 12, 2010

Time:  8:30am Pacific Time

Location: The Ritz-Carlton, San Francisco

Speaker: Michael Narachi, Chief Executive Officer

A live webcast of the presentation can be accessed in the investor relations section of the Orexigen website at http://www.orexigen.com, and will be available for 14 days following the presentation.  Please log in approximately 5 minutes before the scheduled time of the presentation to ensure a timely connection.

About Orexigen Therapeutics

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company has submitted an NDA with the FDA for its lead investigational product, Contrave®.  The Company's second product, Empatic™, has completed Phase 2 clinical development.  Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss, through combination therapeutic approaches.  Further information about the Company can be found at http://www.Orexigen.com.


'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Orexigen(R) Therapeutics to Speak at UBS Global Life Sciences Conference
2. Orexigen(R) Therapeutics to Speak at Upcoming Conferences
3. Orexigen(R) Therapeutics Appoints Mark Booth Chief Commercial Officer
4. Orexigen(R) Therapeutics to Speak at Canaccord Adams Global Growth Conference
5. Orexigen(R) Therapeutics Announces Full Exercise of Overallotment Option by Underwriters
6. Orexigen(R) Therapeutics Presents Additional NB-302 Contrave(R) Data at American Diabetes Association (ADA) 69th Scientific Sessions
7. Orexigen(R) Therapeutics Announces Upcoming Data Presentations at American Diabetes Association and Endocrine Society Annual Scientific Meetings
8. Orexigen(R) Therapeutics to Present at Upcoming Meetings
9. Orexigen(R) Therapeutics Announces Jay Hagan as Senior Vice President, Corporate Development and Strategy
10. Orexigen(R) Therapeutics to Speak at Upcoming Conferences
11. Orexigen(R) Therapeutics Announces First Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2017)... Washington, D.C. (PRWEB) , ... September 19, 2017 ... ... care during an biological outbreak is about to be eliminated, said Lyle Probst, ... makes ExcitePCR’s FireflyDX™ technologies different than other pathogen detection solutions, Probst ...
(Date:9/19/2017)... , ... September 19, 2017 , ... ... technologies for surgical applications, announced today that two new patents have been allowed ... Albert, MD, Co-Founder of Band-LOK, said, “We continue to explore additional clinically-relevant designs ...
(Date:9/17/2017)... ... September 17, 2017 , ... GeneOne Life Science, ... Food and Drug Safety (KMFDS) for an Investigational New Drug application for a ... Syndrome coronavirus (MERS-CoV). The study in Korea represents the second clinical trial for ...
(Date:9/14/2017)... ... September 14, 2017 , ... Boston ... extensive experience with Health Economics and Outcomes Research (HEOR) and ‘big data’ to ... In 2014, US healthcare spending exceeded $3.0 trillion with nearly 1/3 spent on ...
Breaking Biology Technology:
(Date:4/11/2017)... 2017 No two people are believed ... New York University Tandon School of Engineering and ... that partial similarities between prints are common enough ... phones and other electronic devices can be more ... lies in the fact that fingerprint-based authentication systems ...
(Date:4/5/2017)... , April 5, 2017  The Allen Institute for ... Cell Explorer: a one-of-a-kind portal and dynamic digital window ... imaging data, the first application of deep learning to ... stem cell lines and a growing suite of powerful ... for these and future publicly available resources created and ...
(Date:4/4/2017)... April 4, 2017   EyeLock LLC , a ... the United States Patent and Trademark Office (USPTO) has ... the linking of an iris image with a face ... represents the company,s 45 th issued patent. ... very timely given the multi-modal biometric capabilities that have ...
Breaking Biology News(10 mins):